Publication of first clinical evidence for EHO-85 hydrogel

The first clinical evidence related to an hydrogel based on Olea europaea leaf extract (EHO‐85) indicated for the healing of wounds of full and partial thickness has been published in the Journal of Clinical Medicine.

The published article refers to an 8‐week, multicentre, randomized  clinical trial  designed to demonstrate the accelerating effect on wound healing of the novel Olea europaea leaf extract hydrogel (EHO‐85) by comparing it to a widely used amorphous hydrogel.

The intention‐to‐treat analysis was conducted on 195 patients from 23 Spanish health centres/nursing homes.

Results showed that EHO‐85 significantly accelerated wound healing, regardless of ulcer etiology (pressure, venous leg or diabetic foot) and prognosis, doubling the median wound area reduction compared with a reference amorphous hydrogel. This novel treatment balances the ulcer microenvironment by modulating reactive oxygen species and pH. These actions complement the moistening and barrier functions inherent to amorphous hydrogels, whilst also conferring EHO‐85 its documented granulation formation and pain relief properties.

The present randomized controlled trial is a relevant milestone in evidence‐based practice for being the first to demonstrate the effectiveness of an amorphous hydrogel in accelerating wound healing and the superiority of a specific hydrogel based on Olea europaea leaf extract (EHO-85) over another.

Verdú-Soriano J et al. Superiority of a Novel Multifunctional Amorphous Hydrogel Containing Olea europaea Leaf Extract (EHO‐85) for the Treatment of Skin Ulcers: A Randomized, Active‐Controlled Clinical Trial. J. Clin. Med. 2022, 11, 1260. https://doi.org/10.3390/jcm11051260